Company profile: Focal Medical
1.1 - Company Overview
Company description
- Provider of targeted therapeutic products using its patent-protected iontophoresis-based delivery system, including IOP Gemcitabine for locally advanced nonresectable pancreatic cancer, IOP Cisplatin for locally recurrent oral cavity cancer, and a program for targeted delivery of genomic medicine to organs without viral vectors.
Products and services
- IOP Gemcitabine for Pancreatic Cancer: A targeted therapeutic product delivering FDA-approved gemcitabine via iontophoresis for active delivery directly to the pancreas to treat locally advanced, nonresectable pancreatic cancer
- Targeted Delivery of Genomic Medicine: A non-viral targeted delivery program using iontophoresis to deliver genomic medicine directly to target organs without viral vectors for organ-specific administration
- IOP Cisplatin for Oral Cavity Cancer: A patent-protected targeted therapeutic product delivering cisplatin directly to oral cavity tumors using iontophoresis to treat locally recurrent oral cavity cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Focal Medical
Nemera
HQ: France
Website
- Description: Provider of design, development and manufacturing of drug delivery solutions for pharmaceutical, biotechnology and generics industries, covering parenteral, nasal, buccal, auricular, ophthalmic, pulmonary, dermal and transdermal modes of delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nemera company profile →
Nutriband
HQ: United States
Website
- Description: Provider of abuse-deterrent transdermal technologies and drug delivery systems, including the AVERSA platform integrating abuse-deterrent features into patches for fentanyl, buprenorphine, and methylphenidate, and 4P transdermal systems delivering Exenatide for Type 2 Diabetes and FSH for infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nutriband company profile →
Lypro Bio
HQ: United States
Website
- Description: Provider of NanoDisk drug delivery technology to increase solubility and bioavailability of hydrophobic drugs, with applications in cancer (curcumin and all-trans retinoic acid for glioblastoma multiforme and mantle cell lymphoma), infectious diseases (amphotericin B for Leishmania major and Aspergillosis), and neurodegenerative disease research; also offers Ambigent, an antifungal reagent for high-value cell cultures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lypro Bio company profile →
BlueWillow Biologics
HQ: United States
Website
- Description: Provider of intranasal vaccine and adjuvant technologies, including an oil-in-water emulsion Intranasal Adjuvant Technology, NE01 adjuvanted intranasal vaccines, the BW-1010 anthrax vaccine candidate, and a therapeutic peanut allergy vaccine, built on the NanoVax platform to elicit mucosal, cellular, and systemic immunity; also focused on topical antiseptic and anti-infective products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueWillow Biologics company profile →
EryDel
HQ: Italy
Website
- Description: Provider of red blood cell-based drug delivery technologies and therapies. Offers the AIDE platform for autologous intracellular drug encapsulation, the CE marked Red Cell Loader device and EryKit for point-of-care loading, and EryDex, a patient-specific dexamethasone sodium phosphate treatment for Ataxia-Telangiectasia; conducting the NEAT Phase 3 trial evaluating EryDex's neurological effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EryDel company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Focal Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Focal Medical
2.2 - Growth funds investing in similar companies to Focal Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Focal Medical
4.2 - Public trading comparable groups for Focal Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →